TME Pharma NV (XPAR:ALTME) Cash And Cash Equivalents : €3.24 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Cash And Cash Equivalents?

TME Pharma NV's quarterly cash and cash equivalents increased from Dec. 2023 (€2.25 Mil) to Jun. 2024 (€2.70 Mil) and increased from Jun. 2024 (€2.70 Mil) to Dec. 2024 (€3.24 Mil).

TME Pharma NV's annual cash and cash equivalents declined from Dec. 2022 (€4.63 Mil) to Dec. 2023 (€2.25 Mil) but then increased from Dec. 2023 (€2.25 Mil) to Dec. 2024 (€3.24 Mil).

TME Pharma NV Cash And Cash Equivalents Historical Data

The historical data trend for TME Pharma NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Cash And Cash Equivalents Chart

TME Pharma NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

10.30

9.46

4.63

2.25

3.24

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															4.63	3.01	2.25	2.70	3.24

TME Pharma NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

TME Pharma NV (XPAR:ALTME) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

TME Pharma NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines